Gilead Sciences, Inc.
NEWS
The head of GlaxoSmithKline’s pharmaceuticals division is pushing to cut its budget by 20 percent.
Gilead Sciences essentially created a cure for hepatitis C and may be well on its way to developing a cure for HIV-AIDS.
Here are six biotech companies that should benefit the most from research-and-development spending trends that are expected to stimulate biotech development.
On April 23, the FDA’s arthritis advisory committee will take another look at Eli Lilly’s re-submission for their moderate-to-severe rheumatoid arthritis drug.
After serving nearly 30 years with the company Norbert Bischofberger is stepping down from his role as head of research and development and chief scientific officer of Gilead Sciences.
Gilead Sciences announced promising results from a preclinical trial conducted with Beth Israel Deaconess Medical Center as part of an HIV eradication strategy.
Mylan N.V. signed a global collaboration and license deal with Revance Therapeutics to develop and market a biosimilar to Botox.
The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) announced a string of approvals, as well as a couple rejections.
The passing of tax reform led most analysts to predict that 2018 will be a strong year for mergers and acquisitions.
JOBS
IN THE PRESS